Pharmaceutical Care Network Europe

The Pharmaceutical Care Network Europe (PCNE) was established in 1994 by a number of European pharmaceutical care researchers. It became an official association (under Dutch law) in 2004.

Medication Review Drug-related problem classification Guidelines and Indicators

How to become a member

The membership of PCNE is open to any person or institution that does pharmaceutical care research and/or implementation and/or implementation research in Europe. Members must sign a Letter of Intent. This letter basically is a document that stresses the fair relationships between all members, and respect for the intellectual ownership of projects, methods and studies. The Pharmaceutical Care Network Europe also knows Observers. Observers are natural persons or Institutions that live, or have their seat, outside of the goegraphical region Europe, but are also active in pharmaceutical care research. The procedure for becoming an observer is the same as for becoming a member, but but observers have no passive or active voting rights.

After a screening by the board, candidates for membership or observership must present their pharmaceutical care related work to the General Assembly. The members in the General Assembly then decide if the candidate can be a member.

All members (or representatives of Institutional members) at some point during their membership, are expected to be part of the board for a certain period of time (usually 6 years), of which 2 years as chairperson or secretary. Observers, or their representatives cannot be board member.

Lastly, the Pharmaceutical Care Network Europe knows honorary members.

 

The benefits of membership

Annually, PCNE members and observers can share and discuss their pharmaceutical care related projects in the so called 'Soapbox', and ask for, or get advice. They can also open their projects for participation by other members and countries. Members can also announce their work by email to all members in a List, or in a Newsletter that appears every 3 months. Members can also participate in PCNE projects and working groups such as the DRP-classification or Medication Review working group.